AbbVie Headquarters Campus: Innovating Spaces for Biomedical Excellence

 

Details

Location:

Redwood City, California

Client:

Abbvie

Category:

Science + Technology

 

Description

AlfaTech led the turnkey design and construction of AbbVie's groundbreaking 400,000-square-foot headquarters campus, originally envisioned for Abbott Biotherapeutics. Situated at the forefront of biopharmaceutical innovation, this state-of-the-art facility now serves as the epicenter for AbbVie's pioneering research and development endeavors.

The AbbVie Headquarters Campus stands as a testament to AlfaTech's commitment to excellence in design and construction. By seamlessly integrating innovative facilities with a client-focused approach, we have empowered AbbVie to drive groundbreaking advancements in biopharmaceuticals, ultimately improving patients' lives worldwide.

Highlights

  • AlfaTech assumed full responsibility for programming, design, and construction, employing a turnkey approach to deliver a seamlessly integrated campus that exceeds industry standards.

  • The campus features a 4,000 square foot raised floor data center, meticulously designed laboratory facilities, and a sophisticated vivarium for animal care, reflecting AbbVie's commitment to advancing biomedical research.

  • A pilot plant for cell culture and purification was established on the first floor, alongside new laboratory spaces, offices, and service yards, enabling AbbVie to accelerate the development of novel therapeutics.

  • AlfaTech's highly successful single-source project delivery method ensured adherence to budget and schedule commitments, facilitating the seamless execution of this ambitious project.

  • From collaborative office spaces to cutting-edge laboratory facilities, the campus provides a dynamic and inspiring environment for AbbVie's talented team of researchers and professionals.

 
 

Featured Projects

Previous
Previous

Empowering Innovation: AlfaTech's Contribution to the Buck Institute's Stem Cell Research Facility

Next
Next

Revolutionizing Biomedical Research: Terasaki Research Phase 2